Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report

Khalid Al-Baimani, Harman S. Sekhon, Paul Wheatley-Price*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Introduction: About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC. Presentation of case: Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later. Discussion: It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis. Conclusion: This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.

Original languageEnglish
Pages (from-to)6-9
Number of pages4
JournalCancer Treatment Communications
Volume4
DOIs
Publication statusPublished - 2015

Keywords

  • ALK
  • NSCLC
  • Outcome
  • Relapse
  • Stage one

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report'. Together they form a unique fingerprint.

Cite this